Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KYMERA THERAPEUTICS, INC.

(KYMR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kymera Secures FDA Clearance for Phase 1 Trial of KT-413 Relapsed/Refractory B Cell Lymphomas

11/30/2021 | 10:00am EST


ę MT Newswires 2021
All news about KYMERA THERAPEUTICS, INC.
01/18KYMERA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/18Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Boar..
AQ
01/18Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Boar..
CI
01/13INSIDER SELL : Kymera Therapeutics
MT
01/10KYMERA THERAPEUTICS : Investor Presentation, January 2022
PU
01/10Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution in..
GL
01/10Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution in..
GL
01/10Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution in..
CI
01/04Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on ..
AQ
01/03Piper Sandler Adjusts Kymera Therapeutics' Price Target to $91 From $80, Reiterates Ove..
MT
More news
Analyst Recommendations on KYMERA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 84,2 M - -
Net income 2021 -95,0 M - -
Net cash 2021 577 M - -
P/E ratio 2021 -19,1x
Yield 2021 -
Capitalization 1 953 M 1 953 M -
EV / Sales 2021 16,3x
EV / Sales 2022 17,0x
Nbr of Employees 136
Free-Float -
Chart KYMERA THERAPEUTICS, INC.
Duration : Period :
Kymera Therapeutics, Inc. Technical Analysis Chart | KYMR | US5015751044 | MarketScreener
Technical analysis trends KYMERA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 38,04 $
Average target price 79,50 $
Spread / Average Target 109%
EPS Revisions
Managers and Directors
Nello Mainolfi President, Chief Executive Officer & Director
Bruce N. Jacobs Chief Financial Officer
Bruce Lee Booth Chairman
Jared Gollob Chief Medical Officer
Kevin Dushney Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
KYMERA THERAPEUTICS, INC.-40.09%1 953
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508